Literature DB >> 9850067

Differential expression of estrogen receptor-alpha and -beta messenger RNAs as a potential marker of ovarian carcinogenesis.

P Pujol1, J M Rey, P Nirde, P Roger, M Gastaldi, F Laffargue, H Rochefort, T Maudelonde.   

Abstract

Although estrogen receptor (ER)-alpha is expressed in both benign and malignant ovarian tumors, the role of ER in ovarian carcinogenesis of epithelial tumors is still unknown. In view of the recent characterization of ER-beta, a second form of ER that seems to be highly expressed in ovaries, we reexamined this issue by studying the relative expression of ER-alpha and -beta in human ovarian tumor progression. We developed a competitive PCR assay based on coamplification of the two ERs in target nucleotide sequences displaying a high homology (exons 3 and 4). Coamplification experiments with varying amounts of plasmids containing ER-alpha and -beta cDNAs showed that this assay was reliable for discriminating as little as a 2-fold difference in the initial ER-alpha:ER-beta cDNA ratio. The relative expression of ER-alpha compared with ER-beta mRNAs was studied in human ovarian cancer cell lines (n = 5) and in normal ovaries (n = 6), then in human benign and malignant tumor samples including ovarian cysts (n = 24), borderline tumors (n = 3), and cancers (n = 10). In normal ovaries, ER-beta mRNA was the predominant ER form, whereas in ovarian cancer cell lines ER-alpha mRNA was markedly increased as compared with ER-beta. In benign and borderline tumors, ER-beta mRNA was detected in 78% of tumors, whereas ER-alpha mRNA was detected in 29%. In ovarian carcinomas, both ER-alpha and -beta mRNAs were expressed in 80% of tumors. The ER-alpha:ER-beta mRNA ratio was >1 in only one cyst sample (4%). In contrast, the ER-alpha:ER-beta mRNA ratio was markedly increased in ovarian cancers because 60% showed an ER-alpha:ER-beta mRNA >1. In situ hybridization experiments showed overlapping tissular distribution of ER-beta and -alpha expression in cancers and cysts, with a main localization in the epithelium and only a low level of expression in stromal cells. In summary, we found an increase in the ER-alpha:ER-beta mRNA ratio in ovarian carcinomas as compared with normal ovaries and cysts. These data suggest that overexpression of ER-alpha relative to ER-beta mRNA may be a marker of ovarian carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9850067

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  52 in total

1.  ER beta inhibits proliferation and invasion of breast cancer cells.

Authors:  G Lazennec; D Bresson; A Lucas; C Chauveau; F Vignon
Journal:  Endocrinology       Date:  2001-09       Impact factor: 4.736

2.  ERalpha and ERbeta expression and transcriptional activity are differentially regulated by HDAC inhibitors.

Authors:  V Duong; A Licznar; R Margueron; N Boulle; M Busson; M Lacroix; B S Katzenellenbogen; V Cavaillès; G Lazennec
Journal:  Oncogene       Date:  2006-03-16       Impact factor: 9.867

Review 3.  Estrogen receptor beta, a possible tumor suppressor involved in ovarian carcinogenesis.

Authors:  Gwendal Lazennec
Journal:  Cancer Lett       Date:  2006-01-18       Impact factor: 8.679

4.  Estrogen and progesterone receptor status and outcome in epithelial ovarian cancers and low malignant potential tumors.

Authors:  Hugo Arias-Pulido; Harriet O Smith; Nancy E Joste; Therese Bocklage; Clifford R Qualls; Allison Chavez; Eric R Prossnitz; Claire F Verschraegen
Journal:  Gynecol Oncol       Date:  2009-06-27       Impact factor: 5.482

5.  Estrogen receptor beta (ERbeta) protein expression correlates with BAG-1 and prognosis in brain glial tumours.

Authors:  Anna Batistatou; Panayiotis A Kyzas; Ann Goussia; Evdokia Arkoumani; Spyridon Voulgaris; Konstantinos Polyzoidis; Niki J Agnantis; Dimitrios Stefanou
Journal:  J Neurooncol       Date:  2005-11-15       Impact factor: 4.130

Review 6.  Estrogen signaling crosstalk: Implications for endocrine resistance in ovarian cancer.

Authors:  Jennifer R Ribeiro; Richard N Freiman
Journal:  J Steroid Biochem Mol Biol       Date:  2014-02-22       Impact factor: 4.292

Review 7.  Estrogen, male dominance and esophageal adenocarcinoma: is there a link?

Authors:  Huiqi Yang; Olga A Sukocheva; Damian J Hussey; David I Watson
Journal:  World J Gastroenterol       Date:  2012-02-07       Impact factor: 5.742

8.  E4F1, a novel estrogen-responsive gene in possible atheroprotection, revealed by microarray analysis.

Authors:  Yasuhiro Nakamura; Katsuhide Igarashi; Takashi Suzuki; Jun Kanno; Tohru Inoue; Chika Tazawa; Masayuki Saruta; Tomoko Ando; Noriko Moriyama; Toru Furukawa; Masao Ono; Takuya Moriya; Kiyoshi Ito; Haruo Saito; Tadashi Ishibashi; Shoki Takahashi; Shogo Yamada; Hironobu Sasano
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

9.  Estrogen receptor beta (ERbeta) is expressed in brain astrocytic tumors and declines with dedifferentiation of the neoplasm.

Authors:  Anna Batistatou; Dimitrios Stefanou; Anna Goussia; Evdokia Arkoumani; Athanasios G Papavassiliou; Niki J Agnantis
Journal:  J Cancer Res Clin Oncol       Date:  2004-07       Impact factor: 4.553

10.  17beta-Oestradiol treatment modulates nitric oxide synthase activity in MDA231 tumour with implications on growth and radiation response.

Authors:  E C Chinje; K J Williams; B A Telfer; P J Wood; A J van der Kogel; I J Stratford
Journal:  Br J Cancer       Date:  2002-01-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.